TriangleDISEASE & TREATMENT SETTING
Mantle Cell Lymphoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Mantle Cell Lymphoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Mantle Cell Lymphoma. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
10 more-specific settings
Beqalzi: refractory mantle cell lymphoma after prior therapy →Brukinsa: mantle cell lymphoma after prior therapy →Tecartus: refractory mantle cell lymphoma →Calquence: mantle cell lymphoma after prior therapy →Imbruvica: mantle cell lymphoma after prior therapy →JAYPIRCA: refractory mantle cell lymphoma after prior therapy →Revlimid: recurrent mantle cell lymphoma after prior therapy →BREYANZI: refractory mantle cell lymphoma after prior therapy →refractory Mantle Cell Lymphoma →recurrent Mantle Cell Lymphoma →
Study evidence for this setting
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Indication-specific source history
2013-11-13 · Imbruvica (ibrutinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-4e72b51e509ab3d1
- event date
- 2013-11-13
- event kind
- accelerated-approval
- drug or regimen
- Imbruvica (ibrutinib)
- source indication text
- Adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-02aa505229a99f71fe10
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-10-31 · Calquence (acalabrutinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-61242b3c5ca278ad
- event date
- 2017-10-31
- event kind
- accelerated-approval
- drug or regimen
- Calquence (acalabrutinib)
- source indication text
- Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9012288ff17cbdf6da3b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-11-14 · Brukinsa (zanubrutinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-6274838c71046550
- event date
- 2019-11-14
- event kind
- accelerated-approval
- drug or regimen
- Brukinsa (zanubrutinib)
- source indication text
- Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-5ecb3872ea18a4986f48
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-07-24 · Tecartus (brexucabtagene autoleucel) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-04e2e60bc99c19d3
- event date
- 2020-07-24
- event kind
- accelerated-approval
- drug or regimen
- Tecartus (brexucabtagene autoleucel)
- source indication text
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b5d3c853ddc4e9301e35
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-05-18 · Imbruvica (ibrutinib) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-bc2f593171e050ea
- event date
- 2023-05-18
- event kind
- withdrawal
- drug or regimen
- Imbruvica (ibrutinib)
- source indication text
- Adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-02aa505229a99f71fe10
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-01-16 · Calquence (acalabrutinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-d82285bcc9992866
- event date
- 2025-01-16
- event kind
- traditional-approval
- drug or regimen
- Calquence (acalabrutinib)
- source indication text
- Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9012288ff17cbdf6da3b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-01-16 · acalabrutinib with bendamustine and rituximab · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- notice-969dff9387480266
- event date
- 2025-01-16
- event kind
- approval-notification
- drug or regimen
- acalabrutinib with bendamustine and rituximab
- source indication text
- FDA approved acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation .
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- traditional
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-7fa68eece0cf7e41
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-13 · Beqalzi (sonrotoclax) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- fda-17e67f73de17f8ad
- event date
- 2026-05-13
- event kind
- accelerated-approval
- drug or regimen
- Beqalzi (sonrotoclax)
- source indication text
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b902c006dd7cbee0434b
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-13 · sonrotoclax · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- event id
- notice-88c3b5f47ed0596c
- event date
- 2026-05-13
- event kind
- approval-notification
- drug or regimen
- sonrotoclax
- source indication text
- FDA approved sonrotoclax, a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor.
- match phrase
- mantle cell lymphoma
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-e3ca63e98a156ea8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-mantle-cell-lymphoma
- binding id
- ncit-C4337
- source collection
- ncit-concept
- source key
- C4337
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice